145 related articles for article (PubMed ID: 10698495)
21. C-myc-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent.
Trudel M; Lanoix J; Barisoni L; Blouin MJ; Desforges M; L'Italien C; D'Agati V
J Exp Med; 1997 Dec; 186(11):1873-84. PubMed ID: 9382886
[TBL] [Abstract][Full Text] [Related]
22. RRR-alpha-tocopheryl succinate inhibits EL4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest.
Yu W; Sanders BG; Kline K
Nutr Cancer; 1997; 27(1):92-101. PubMed ID: 8970189
[TBL] [Abstract][Full Text] [Related]
23. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW; Blyth K; Cameron ER; Neil JC
J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
[TBL] [Abstract][Full Text] [Related]
24. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis.
Hsu B; Marin MC; el-Naggar AK; Stephens LC; Brisbay S; McDonnell TJ
Oncogene; 1995 Jul; 11(1):175-9. PubMed ID: 7624125
[TBL] [Abstract][Full Text] [Related]
25. Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts.
Solomon DL; Philipp A; Land H; Eilers M
Oncogene; 1995 Nov; 11(9):1893-7. PubMed ID: 7478619
[TBL] [Abstract][Full Text] [Related]
26. c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli.
Kuttler F; Amé P; Clark H; Haughey C; Mougin C; Cahn JY; Dang CV; Raffeld M; Fest T
Oncogene; 2001 Sep; 20(42):6084-94. PubMed ID: 11593416
[TBL] [Abstract][Full Text] [Related]
27. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice.
de La Coste A; Mignon A; Fabre M; Gilbert E; Porteu A; Van Dyke T; Kahn A; Perret C
Cancer Res; 1999 Oct; 59(19):5017-22. PubMed ID: 10519417
[TBL] [Abstract][Full Text] [Related]
28. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
29. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
Wang Y; Szekely L; Okan I; Klein G; Wiman KG
Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.
Graeber TG; Osmanian C; Jacks T; Housman DE; Koch CJ; Lowe SW; Giaccia AJ
Nature; 1996 Jan; 379(6560):88-91. PubMed ID: 8538748
[TBL] [Abstract][Full Text] [Related]
31. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
32. Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones.
Biroccio A; Amodei S; Benassi B; Scarsella M; Cianciulli A; Mottolese M; Del Bufalo D; Leonetti C; Zupi G
Oncogene; 2002 May; 21(19):3011-9. PubMed ID: 12082531
[TBL] [Abstract][Full Text] [Related]
33. Myc lacks E2F1's ability to suppress skin carcinogenesis.
Rounbehler RJ; Schneider-Broussard R; Conti CJ; Johnson DG
Oncogene; 2001 Aug; 20(38):5341-9. PubMed ID: 11536046
[TBL] [Abstract][Full Text] [Related]
34. Signaling through the antigen receptor of B lymphocytes activates a p53-independent pathway of c-Myc-induced apoptosis.
Hagiyama H; Adachi T; Yoshida T; Nomura T; Miyasaka N; Honjo T; Tsubata T
Oncogene; 1999 Jul; 18(28):4091-8. PubMed ID: 10435590
[TBL] [Abstract][Full Text] [Related]
35. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
36. Differential regulation of the clusterin gene by Ha-ras and c-myc oncogenes and during apoptosis.
Klock G; Storch S; Rickert J; Gutacker C; Koch-Brandt C
J Cell Physiol; 1998 Dec; 177(4):593-605. PubMed ID: 10092212
[TBL] [Abstract][Full Text] [Related]
37. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc.
Allen JD; Verhoeven E; Domen J; van der Valk M; Berns A
Oncogene; 1997 Sep; 15(10):1133-41. PubMed ID: 9294606
[TBL] [Abstract][Full Text] [Related]
38. Conditional expression and oncogenicity of c-myc linked to a CD2 gene dominant control region.
Stewart M; Cameron E; Campbell M; McFarlane R; Toth S; Lang K; Onions D; Neil JC
Int J Cancer; 1993 Apr; 53(6):1023-30. PubMed ID: 8473043
[TBL] [Abstract][Full Text] [Related]
39. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
40. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
